Profil bibliographique

Florian Hiemeyer

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

77Publications signalées

2627Citations signalées

1Affiliations récentes

Les institutions déclarées

Bayer (Germany)

Les domaines associés

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentCancer Immunotherapy and BiomarkersViral-associated cancers and disordersHER2/EGFR in Cancer Research

Les publications récentes

2025 article OpenAlex

panSOHO: Phase II trial of BAY 2927088 in patients with unresectable or metastatic solid tumors other than NSCLC with HER2 -activating mutations.

Vivek Subbiah, Bradley A. McGregor, Ecaterina E. Dumbrava, Antoîne Italiano et autres

us, fr, es, jp, au, ch, de, it (code pays fourni par la source)

2 citations Journal of Clinical Oncology

Accès ouvert 2025 other OpenAlex

Figure S3 from Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors

Benedito A. Carneiro, Robert M. Jotte, Nashat Gabrail, Kristopher Wentzel et autres

0 citations

Accès ouvert 2025 other OpenAlex

Figure 3 from Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors

Benedito A. Carneiro, Robert M. Jotte, Nashat Gabrail, Kristopher Wentzel et autres

0 citations

Accès ouvert 2025 other OpenAlex

Table 3 from Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors

Benedito A. Carneiro, Robert M. Jotte, Nashat Gabrail, Kristopher Wentzel et autres

0 citations

Accès ouvert 2025 other OpenAlex

Table S1 from Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors

Benedito A. Carneiro, Robert M. Jotte, Nashat Gabrail, Kristopher Wentzel et autres

0 citations

Accès ouvert 2025 other OpenAlex

Figure 2 from Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors

Benedito A. Carneiro, Robert M. Jotte, Nashat Gabrail, Kristopher Wentzel et autres

0 citations

Accès ouvert 2025 other OpenAlex

Figure S1 from Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors

Benedito A. Carneiro, Robert M. Jotte, Nashat Gabrail, Kristopher Wentzel et autres

0 citations

Accès ouvert 2025 other OpenAlex

Figure 1 from Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors

Benedito A. Carneiro, Robert M. Jotte, Nashat Gabrail, Kristopher Wentzel et autres

0 citations

Accès ouvert 2025 other OpenAlex

Figure S2 from Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors

Benedito A. Carneiro, Robert M. Jotte, Nashat Gabrail, Kristopher Wentzel et autres

0 citations

Accès ouvert 2025 other OpenAlex

Table S2 from Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors

Benedito A. Carneiro, Robert M. Jotte, Nashat Gabrail, Kristopher Wentzel et autres

0 citations

Accès ouvert 2025 other OpenAlex

Table 1 from Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors

Benedito A. Carneiro, Robert M. Jotte, Nashat Gabrail, Kristopher Wentzel et autres

0 citations

Accès ouvert 2025 other OpenAlex

Data from Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors

Benedito A. Carneiro, Robert M. Jotte, Nashat Gabrail, Kristopher Wentzel et autres

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.